Skip to main content
AMP 2025 Annual Meeting & Expo Main banner
Final Program


    C. Ola Landgren, MD, PhD (he/him/his)

    Chief of Myeloma Division, Director of Myeloma Research Institute
    University of Miami, Sylvester Comprehensive Cancer Center
    Pinecrest, Florida, United States

    I am an MD/PhD Hematology/Oncology specialist with almost 30 years of leadership experience in translational cancer medicine. Over the past two decades, I have served as the leader for large programs at the National Cancer Institute/National Institutes of Health (NCI/NIH), Memorial Sloan Kettering Cancer Center (MSKCC), and University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC).

    Currently, I am a Professor of Medicine, Leader of the Translational and Clinical Oncology program, Chief of the Division of Myeloma, and Director of the Myeloma Research Institute at UM/SCCC. Before joining UM/SCCC in 2020, I served as Chief of the Myeloma Service at MSKCC and was Professor Medicine at Cornell Medical College from 2014 to 2020. Prior to that, I served as Senior Investigator and Chief of the Multiple Myeloma Section at the Intramural Program of the NCI/NIH from 2004 to 2014. Prior to joining NCI/NIH, I earned my MD and PhD at Karolinska Institute in Stockholm, Sweden.

    Throughout my career, my clinical and scientific focus has been on the development of novel treatment strategies for patients with myeloma, partnered with molecular profiling (personalized oncology) and development of technologies for minimal residual disease (MRD) assessment: targeted detection/intervention to prevent, find, and treat.

    I have published over 450 peer-reviewed articles in high impact journals, including Nature Communications, Nature Medicine, Blood, Journal of American Medical Association, Lancet, Lancet Oncology, JAMA Oncology, Journal of Clinical Oncology, and the New England Journal of Medicine. Numerous times, I have chaired sessions and presented data at international conferences including American Society of Hematology (ASH), European Hematology Association (EHA), and the American Society of Clinical Oncology (ASCO). I am a member of American Society of Clinical Investigation (ASCI).

    Disclosure information not submitted.

    Presentation(s):